Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 27.58 1.25% 0.34
RYTM closed up 1.25 percent on Monday, December 10, 2018, on 82 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical RYTM trend table...

Date Alert Name Type % Chg
Dec 10 Lower Bollinger Band Touch Weakness 0.00%
Dec 7 200 DMA Resistance Bearish 1.25%
Dec 7 20 DMA Resistance Bearish 1.25%
Dec 7 50 DMA Resistance Bearish 1.25%
Dec 7 MACD Bearish Centerline Cross Bearish 1.25%
Dec 7 180 Bearish Setup Bearish Swing Setup 1.25%
Dec 6 50 DMA Resistance Bearish -1.01%
Dec 6 Pocket Pivot Bullish Swing Setup -1.01%
Dec 6 Lower Bollinger Band Touch Weakness -1.01%
Dec 4 Fell Below 200 DMA Bearish 0.62%

Older signals for RYTM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
Is RYTM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 37.23
52 Week Low 16.8
Average Volume 135,142
200-Day Moving Average 28.4508
50-Day Moving Average 27.9224
20-Day Moving Average 28.1935
10-Day Moving Average 28.458
Average True Range 1.9009
ADX 12.22
+DI 14.4917
-DI 23.4119
Chandelier Exit (Long, 3 ATRs ) 26.2973
Chandelier Exit (Short, 3 ATRs ) 30.2627
Upper Bollinger Band 29.9374
Lower Bollinger Band 26.4496
Percent B (%b) 0.32
BandWidth 12.370937
MACD Line -0.131
MACD Signal Line 0.0045
MACD Histogram -0.1355
Fundamentals Value
Market Cap 719.13 Million
Num Shares 26.1 Million
EPS -3.13
Price-to-Earnings (P/E) Ratio -8.81
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.79
Resistance 3 (R3) 29.60 28.67 29.42
Resistance 2 (R2) 28.67 28.11 28.77 29.30
Resistance 1 (R1) 28.13 27.76 28.40 28.32 29.18
Pivot Point 27.20 27.20 27.34 27.29 27.20
Support 1 (S1) 26.65 26.63 26.93 26.84 25.98
Support 2 (S2) 25.72 26.29 25.82 25.86
Support 3 (S3) 25.18 25.72 25.74
Support 4 (S4) 25.37